Vir Biotechnology Inc (NASDAQ: VIR) kicked off on Monday, down -7.41% from the previous trading day, before settling in for the closing price of $7.96. Over the past 52 weeks, VIR has traded in a range of $6.56-$14.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 423.44% over the past five years. While this was happening, its average annual earnings per share was recorded 12.21%. With a float of $87.38 million, this company’s outstanding shares have now reached $136.96 million.
Let’s look at the performance matrix of the company that is accounted for 408 employees. In terms of profitability, gross margin is 86.84%, operating margin of -707.97%, and the pretax margin is -715.51%.
Vir Biotechnology Inc (VIR) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Vir Biotechnology Inc is 36.28%, while institutional ownership is 51.37%. The most recent insider transaction that took place on Feb 26 ’25, was worth 67,402. In this transaction EVP and General Counsel of this company sold 7,373 shares at a rate of $9.14, taking the stock ownership to the 79,460 shares. Before that another transaction happened on Feb 26 ’25, when Company’s Officer proposed sale 7,373 for $9.10, making the entire transaction worth $67,094.
Vir Biotechnology Inc (VIR) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.83 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.21% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.12% during the next five years compared to -18.74% drop over the previous five years of trading.
Vir Biotechnology Inc (NASDAQ: VIR) Trading Performance Indicators
Take a look at Vir Biotechnology Inc’s (VIR) current performance indicators. Last quarter, stock had a quick ratio of 8.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.83, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.07 in one year’s time.
Technical Analysis of Vir Biotechnology Inc (VIR)
Vir Biotechnology Inc (NASDAQ: VIR) saw its 5-day average volume 1.3 million, a negative change from its year-to-date volume of 2.33 million. As of the previous 9 days, the stock’s Stochastic %D was 13.65%. Additionally, its Average True Range was 0.62.
During the past 100 days, Vir Biotechnology Inc’s (VIR) raw stochastic average was set at 10.27%, which indicates a significant increase from 4.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.49% in the past 14 days, which was lower than the 103.92% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.33, while its 200-day Moving Average is $8.83. Nevertheless, the first resistance level for the watch stands at $7.72 in the near term. At $8.08, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.31. If the price goes on to break the first support level at $7.13, it is likely to go to the next support level at $6.90. The third support level lies at $6.54 if the price breaches the second support level.
Vir Biotechnology Inc (NASDAQ: VIR) Key Stats
The company with the Market Capitalisation of 1.01 billion has total of 137,143K Shares Outstanding. Its annual sales at the moment are 74,210 K in contrast with the sum of -521,960 K annual income. Company’s last quarter sales were recorded 12,370 K and last quarter income was -104,590 K.
